DeepLook Medical and NHS Oxford University UK announce new study
- DeepLook Medical

- Oct 26
- 3 min read

DeepLook Medical Partners with Oxford NHS Hospitals to Launch AI Study for Dense Breast Cancer Detection
Oxford UK and Phoenix, AZ, October 27, 2025: DeepLook Medical, a leader in visual enhancement technology to advance medical imaging, has announced the launch of PRECISION-DTI (Project to Review Enhanced Cancer Identification through Sensitivity and Specificity Improvements in Dense Tissue Interpretation), a clinical study designed to demonstrate that its imaging technology, DL Precise™, enables doctors to visualize breast cancers that are frequently missed in dense breast tissue. The study will be conducted at Oxford University Hospitals NHS Foundation Trust under the leadership of Dr. Sarim Ather, Co-Director Oxford Clinical AI and Dr. Aya Deabes, Consultant Breast Radiologist.
Dense breast tissue is a major challenge in breast cancer screening. It can mask tumors on mammograms, making cancers harder to detect and increasing the likelihood of delayed diagnoses. Data shows around 40% of women have dense breasts, and standard screening methods can miss cancers in dense breast tissue.
PRECISION-DTI will examine how DL Precise™ impacts radiologists’ accuracy, confidence, and decision-making. The study will include 400 real patient cases with corresponding mammograms and ultrasound images, covering a wide range of ages, breast densities, and cancer types. DL Precise™ is UK cleared, and has begun commercial distribution.
“With breast cancer costs in the UK projected to reach £3.6 billion annually by 2034, it is critical that we prioritize clinically validated technologies. DeepLook Medical’s DL Precise™ offers AI-powered enhancements designed to uncover cancers often hidden in dense tissue. Through PRECISION-DTI, we aim to show how this innovation can strengthen radiologists’ capabilities, enable earlier detection, and ultimately reduce both the human and economic toll of breast cancer.” said Dr. Sarim Ather
Doctors participating in the study will read each case twice, first using standard imaging, and then with the AI-generated measurements and overlays provided by DL Precise™. Researchers will evaluate whether the technology improves:
Accuracy of biopsy recommendations
Early cancer detection, including cancers often missed in dense tissue
Doctors’ confidence in classifying findings
Consistency among radiologists of different experience levels
Efficiency of interpretation
“Breast cancer is the most common cancer in the UK and demands early diagnosis to achieve over 90% five-year survival rates. Yet, dense breast tissue often obscures cancers in standard mammograms, creating a huge gap in patient care. We need to embrace new technologies to give patients the best care possible, uncovering hidden findings and delivering precise diagnostic insights to guide informed, confident health decisions.” said Dr. Aya Deabes.
The collaboration between DeepLook Medical and Oxford University Hospitals aims to generate data that could inform future breast cancer screening practices and support earlier, more accurate detection.
“Women with dense breast tissue deserve the same chance at early detection as anyone else, yet too often their cancers remain hidden. Partnering with Oxford University Hospitals, an institution at the forefront of medical research, enables us to further demonstrate how DL Precise™ can support radiologists in addressing this critical gap. Together, we’re working to advance women’s health and ensure more women receive timely, accurate diagnoses.” said Marissa Fayer, CEO, DeepLook Medical.
About DeepLook Medical
DeepLook Medical focuses on visual enhancement technology to advance medical imaging. DL Precise™ is the first in a series of innovative products using the company’s unique shape-recognition software to delineate the details of tumor morphology – a key to better diagnosis and treatment across the field of oncology. The company is leveraging other complementary AI advances to further the reach and impact of its patented technology. To learn more, please visit: https://www.deeplookmedical.com/
Read more here.




Comments